Nxera Pharma Co., Ltd.

Tokyo Stock Exchange 4565.T

Nxera Pharma Co., Ltd. Cash and Short-Term Investments for the year ending December 31, 2023: USD 347.72 M

Nxera Pharma Co., Ltd. Cash and Short-Term Investments is USD 347.72 M for the year ending December 31, 2023, a -31.47% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Nxera Pharma Co., Ltd. Cash and Short-Term Investments for the year ending December 31, 2022 was USD 507.43 M, a -2.91% change year over year.
Nxera Pharma Co., Ltd. Cash and Short-Term Investments for the year ending December 31, 2021 was USD 522.66 M, a 35.00% change year over year.
Nxera Pharma Co., Ltd. Cash and Short-Term Investments for the year ending December 31, 2020 was USD 387.16 M, a 173.71% change year over year.
Nxera Pharma Co., Ltd. Cash and Short-Term Investments for the year ending December 31, 2019 was USD 141.45 M, a -17.34% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

Tokyo Stock Exchange: 4565.T

Nxera Pharma Co., Ltd.

CEO	Mr. Christopher Cargill
IPO Date	July 29, 2004
Location	Japan
Headquarters	PMO Hanzomon
Employees	372
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company's development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders. It is also involved in the development of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; and other discovery and preclinical stage drugs. Nxera Pharma Co., Ltd. has a strategic collaboration with AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years